Genetic validation of neurokinin 3 receptor antagonists for ischemic heart disease prevention in men - A one-sample Mendelian randomization study.
Study design not specified in the source record · EBioMedicine · 2022. Source record refreshed; an explanation has not been reviewed.
About this paper
This page identifies the publication and its source. A checked explanation of its findings is not yet available.
Reading this record
Checking bibliographic metadata does not verify a study’s conclusions or any advice previously linked to it.
Publication details
Genetic validation of neurokinin 3 receptor antagonists for ischemic heart disease prevention in men - A one-sample Mendelian randomization study.
Schooling CM
EBioMedicine · 2022
- PubMed ID
- 35231698
- Record checked
A checked publication record confirms source details. It does not verify a health claim or assess the quality of the study. Our approach.
Keep your place in the research.
Save this source or mark it as read.